Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Sees Significant Increase in Short Interest

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 942,551 shares, an increase of 3,584.7% from the May 31st total of 25,580 shares. Based on an average trading volume of 28,446,970 shares, the short-interest ratio is currently 0.0 days. Currently, 79.8% of the shares of the company are short sold.

Regentis Biomaterials Stock Performance

NYSEAMERICAN:RGNT opened at $4.15 on Friday. Regentis Biomaterials has a 12-month low of $1.23 and a 12-month high of $15.50. The company has a 50 day simple moving average of $2.79.

Analysts Set New Price Targets

Separately, ThinkEquity upgraded shares of Regentis Biomaterials to a “strong-buy” rating in a research note on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Strong Buy”.

Institutional Investors Weigh In On Regentis Biomaterials

An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC purchased a new stake in shares of Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned about 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.